Drugs / Nelistotug
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05277051 | Mar 2022 → Aug 2027 expected | neoplasm | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04446351 | Jun 2020 → Dec 2026 expected | neoplasm | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06062420 | Nov 2023 → Sep 2026 expected | head and neck carcinoma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05565378 | Oct 2022 → Nov 2026 expected | non-small cell lung carcinoma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06926673 | Dec 2021 → May 2024 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT03739710 | Jan 2019 → May 2024 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nelistotug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05565378 ↗ |
| Known as | GSK6097608 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03739710 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5315022 ↗ |
| Route | Intravenous | “GSK6097608 will be administered as an IV infusion.” NCT04446351 ↗ |